Duration of efficacy and metabolic characteristics of brigatinib/brigatinib (Embry)

Brigatinib/Brigatinib (Brigatinib) is a highly effective targeted therapy drug. Its duration of efficacy and metabolic characteristics give it important advantages in the treatment of ALK-positive non-small cell lung cancer (NSCLC). The pharmacokinetic properties of brigatinib determine its absorption, distribution, metabolism and excretion processes in the body, as well as its therapeutic effect.

After oral administration of brigatinib, its plasma concentration (Cmax) and the area of the plasma concentration-time curve (AUC) are dose-dependent. At a dose of 90 mg, the Cmax of brigatinib is approximately 552 ng/ml and the AUC is 8165 ng·h/ml. When the dose was increased to 180 mg, Cmax increased to 1452 ng/ml and AUC increased to 20276 ng·h/ml. This shows that the efficacy of brigatinib increases with increasing dose, and its pharmacokinetic properties show good dose dependence.

The metabolism of brigatinib is mainly carried out by the liver enzyme system, especially through the action of CYP3A enzyme. The drug is absorbed relatively quickly in the body, and peak plasma concentration (Tmax) is usually reached within 1 to 4 hours after oral administration. However, the absorption of brigatinib is affected by food. Studies have shown that the Cmax of brigatinib will be reduced by approximately 13% after consuming a high-fat meal, but the impact on AUC will be small. This means that brigatinib can be taken before or after meals, and its bioavailability does not change significantly across different feeding states.

During long-term use, brigatinib shows relatively stable drug accumulation, and the accumulation ratio is usually between 1.9 and 2.4. This shows that during the treatment process, the plasma concentration of brigatinib is relatively stable, helping to achieve sustained efficacy. In addition, brigatinib has a long half-life, allowing it to provide a stable therapeutic effect, and patients can take it once daily, improving treatment compliance.

Reference materials:https://www.alunbrig.com/